Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The British Heart Foundation Health Promotion Research Group, based in the Nuffield Department of Population Health, has been officially designated as a World Health Organization (WHO) Collaborating Centre.

The new centre will be known as the British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention. The launch of this centre will be held on the Monday the 28th of April from 10.00 am to 12.00 at the Richard Doll Building, Old Road Campus in Oxford.

The overall aim of the centre is to carry out research of the highest methodological quality that has the greatest possible influence on public health policy and practice, as it relates to the primary prevention of non-communicable disease (NCD).

The centre has five main research themes. They are:

  • Diet and nutrition
  • Physical activity
  • Obesity
  • Environmental sustainability
  • Cardiovascular disease epidemiology

As a WHO Collaborating Centre it will be:

  • Working with WHO in capacity building for population level approaches for NCD prevention
  • Contributing to WHO's work in the development of guidelines/manuals on population level NCD prevention.
  • Assisting WHO to develop methods for evaluating population level NCD prevention programmes including training programmes.
  • Providing WHO with statistical analysis and systematic reviews related to population level NCD prevention.

The United Nations meeting of the on the prevention and control of NCDs in September 2011 has resulted in a greater focus on population approaches to prevent NCDs, such as cardiovascular disease, cancer, diabetes and chronic respiratory disease.

Many countries are now considering and implementing population approaches to NCD prevention which include measures such as taxes on tobacco, alcohol and unhealthy foods, , bans on the advertising  of such products, providing better information about unhealthy products, and the provision of better facilities for active travel and recreation involving physical activity.

Evidence on the effectiveness of population approaches to NCD prevention is vitally important to make inform governments and other policy makers concerned about the rising burden of NCDs. This new centre will play a leading role in providing such evidence and help to build the capacity locally and internationally for population approaches for NCD prevention., 

For enquiries relating to the WHO Collaborating Centre’s activities please contact:

Dr Mike Rayner (mike.rayner@dph.ox.ac.uk) or Dr Kremlin Wickramasinghe (kremlin.wickramasinghe@dph.ox.ac.uk)

Similar stories

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

No benefit of convalescent plasma for critically ill COVID-19 patients

A large study of over 2000 COVID-19 patients has found that giving critically ill patients blood plasma from recovered COVID-19 patients did not significantly reduce deaths, or the need for intensive care support such as being put on a ventilator machine.

Increased infectiousness of coronavirus variants explained

Researchers from the Universities of Oxford and Dundee have made a discovery that helps explain why variations in the virus causes COVID-19 to spread so rapidly.